Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 96

Similar articles for PubMed (Select 16614544)

1.

Does the clinical course of depression determine improvement in symptoms and quality of life?

Moses T, Leuchter AF, Cook I, Abrams M.

J Nerv Ment Dis. 2006 Apr;194(4):241-8.

PMID:
16614544
2.

Significant improvement in the quality of life of Brazilian depressed outpatients 12 weeks following the start of antidepressants.

Berlim MT, Pargendler J, Brenner J, Fleck MP.

Psychiatry Res. 2007 Dec 3;153(3):253-9. Epub 2007 Aug 1.

PMID:
17675247
3.

Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.

Henkel V, Seemüller F, Obermeier M, Adli M, Bauer M, Mundt C, Brieger P, Laux G, Bender W, Heuser I, Zeiler J, Gaebel W, Mayr A, Möller HJ, Riedel M.

J Affect Disord. 2009 Jun;115(3):439-49. doi: 10.1016/j.jad.2008.10.011. Epub 2008 Nov 22.

PMID:
19027961
4.

Subject expectations of treatment effectiveness and outcome of treatment with an experimental antidepressant.

Krell HV, Leuchter AF, Morgan M, Cook IA, Abrams M.

J Clin Psychiatry. 2004 Sep;65(9):1174-9.

PMID:
15367043
5.

Do stressful life events predict medical treatment outcome in first episode of depression?

Bock C, Bukh JD, Vinberg M, Gether U, Kessing LV.

Soc Psychiatry Psychiatr Epidemiol. 2009 Sep;44(9):752-60. doi: 10.1007/s00127-008-0491-1. Epub 2009 Feb 5.

PMID:
19209372
6.

Adverse life events and cognitive-personality characteristics in the prediction of major depression and antidepressant response.

Mazure CM, Bruce ML, Maciejewski PK, Jacobs SC.

Am J Psychiatry. 2000 Jun;157(6):896-903.

PMID:
10831468
7.

Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials.

Kornstein SG, Wohlreich MM, Mallinckrodt CH, Watkin JG, Stewart DE.

J Clin Psychiatry. 2006 May;67(5):761-70.

PMID:
16841626
8.

Impact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorder.

Demyttenaere K, Andersen HF, Reines EH.

Int Clin Psychopharmacol. 2008 Sep;23(5):276-86. doi: 10.1097/YIC.0b013e328303ac5f.

PMID:
18703937
9.

[Use of antidepressant drugs in schizophrenic patients with depression].

Micallef J, Fakra E, Blin O.

Encephale. 2006 Mar-Apr;32(2 Pt 1):263-9. Review. French.

PMID:
16910628
10.

Quality of life outcomes among patients with depression after 6 months of starting treatment: results from FINDER.

Reed C, Monz BU, Perahia DG, Gandhi P, Bauer M, Dantchev N, Demyttenaere K, Garcia-Cebrian A, Grassi L, Quail D, Tylee A, Montejo AL.

J Affect Disord. 2009 Mar;113(3):296-302. doi: 10.1016/j.jad.2008.05.021. Epub 2008 Jul 7.

PMID:
18603303
11.

Can sociodemographic and clinical variables predict the quality of life of outpatients with major depression?

Berlim MT, McGirr A, Fleck MP.

Psychiatry Res. 2008 Sep 30;160(3):364-71. doi: 10.1016/j.psychres.2007.07.024. Epub 2008 Aug 19.

PMID:
18715654
12.

Response to 4-month treatment with reboxetine in Parkinson's disease patients with a major depressive episode.

Pintor L, Baillès E, Valldeoriola F, Tolosa E, Martí MJ, de Pablo J.

Gen Hosp Psychiatry. 2006 Jan-Feb;28(1):59-64.

PMID:
16377367
14.

Time course of response to antidepressants in late-life major depression: therapeutic implications.

Whyte EM, Dew MA, Gildengers A, Lenze EJ, Bharucha A, Mulsant BH, Reynolds CF.

Drugs Aging. 2004;21(8):531-54. Review.

PMID:
15182217
15.

The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach.

Duru G, Fantino B.

Curr Med Res Opin. 2008 May;24(5):1329-35. doi: 10.1185/030079908X291958 . Epub 2008 Mar 28.

PMID:
18377706
16.
17.

An innovative design to establish proof of concept of the antidepressant effects of the NR2B subunit selective N-methyl-D-aspartate antagonist, CP-101,606, in patients with treatment-refractory major depressive disorder.

Preskorn SH, Baker B, Kolluri S, Menniti FS, Krams M, Landen JW.

J Clin Psychopharmacol. 2008 Dec;28(6):631-7. doi: 10.1097/JCP.0b013e31818a6cea.

PMID:
19011431
18.

Time course of response to antidepressants: predictive value of early improvement and effect of additional psychotherapy.

van Calker D, Zobel I, Dykierek P, Deimel CM, Kech S, Lieb K, Berger M, Schramm E.

J Affect Disord. 2009 Apr;114(1-3):243-53. doi: 10.1016/j.jad.2008.07.023. Epub 2008 Oct 11.

PMID:
18849079
19.

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.

Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK.

Arch Gen Psychiatry. 2006 Aug;63(8):856-64.

PMID:
16894061
20.

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder.

Septien-Velez L, Pitrosky B, Padmanabhan SK, Germain JM, Tourian KA.

Int Clin Psychopharmacol. 2007 Nov;22(6):338-47.

PMID:
17917552
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk